Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularization from age-related macular degeneration

International Ophthalmology Clinics

Volumn 44, Issue 3, 2004, Pages 23-32

  Barouch, Fina C ^a   Miller, Joan W ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BENZOPORPHYRIN DERIVATIVE; ENDOSTATIN; MIDOSTAURIN; PEGAPTANIB; RANIBIZUMAB; STAUROSPORINE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SCREENING; GENE THERAPY; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; GENE THERAPY; HUMANS; MACULAR DEGENERATION; OLIGONUCLEOTIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3242663235     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404430-00005     Document Type: Review

References (60)

1. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther. 2001;12:2029-2032.
2. Hyman L. Epidemiology of eye disease in the elderly. Eye. 1987;1:330-341.
3. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1109-1114.
4. Campochiaro PA, Soloway P, Ryan SJ, et al. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis. 1999;5:34-38.
5. Green WR, Enger C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology. 1993;100:1519-1535.
6. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1990;108:816-824.
7. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991;109:1219-1230.
8. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117:1329-1345.
9. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol. 2001;119:198-207.
10. Bressler NM, Arnold J, Benchaboune M, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol. 2002;120:1443-1454.
11. Blumenkranz MS, Bressler NM, Bressler SB, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials-TAP Report no. 5. Arch Ophthalmol. 2002;120:1307-1314.
12. Blinder KJ, Bradley S, Bressler NM, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group and Verteporfin in Photodynamic Therapy (VIP) Study Group. Effect of baseline lesion size, visual acuity, and lesion composition on visual acuity change from baseline with and without verteporfin therapy in choroidal neovascularization secondary to age-related macular degeneration. TAP and VIP report no. 1. Am J Ophthalmol. 2003;136:407-418.
13. Carmeliet P, Ferreira V, Breir G, et al. Abnormal blood vessel development and lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:435-439.
14. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
15. Ferrara N, Houck K, Jakeman L, et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13:18-31.
16. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
17. Shima D, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the sole mitogen. Mol Med. 1995;2:182-193.
18. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of VEGF produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103:1820-1828.
19. Adamis AP, Miller JW, Bernal M, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
20. Miller J, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate mode. Am J Pathol 1994;145:574-584.
21. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
22. Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
23. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-10461.
24. Aiello LP, Pierce EA, Foley ED, et al. Vascular endothelial growth factor and the eye: Biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 1997;29:354-362.
25. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
26. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
27. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol. 1994;112:1476-1482.
28. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995;72:638-645.
29. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 1997;29:354-362.
30. Lip PL, Blann AD, Hope-Ross M, et al. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology. 2001;108:705-710.
31. Blaauwgeers HGT, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Am J Pathol. 1999;155:421-428.
32. Husain D, Ambati B, Adamis AP, et al. Mechanism of age related macular degeneration. Ophthalmol Clin North Am. 2002;15:87-91.
33. Lopez FP, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
34. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122:393-403.
35. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
36. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81:154-162.
37. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000;157:135-144.
38. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of VEGF prevents ocular neovascularization in a non-human primate. Arch Ophthalmol. 1996;114:66-71.
39. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-346.
40. Gauthier D, Husain D, Kim IK, et al. Safety and efficacy of intravitreal injection of rhuFab VEGF in combination with verteporfin PDT on experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2002;43:E-abstract 566.
41. Heier JS, Greene WL, rhuFabV2 Study Group. RhuFabV2 (an anti-VEGF antibody fragment) in neovascular AMD: Safety and tolerability of multiple intravitreal injections. Invest Ophthalmol Vis Sci. 2002;43:E-abstract 2520.
42. The Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143-152.
43. Singerman LJ. Eyetech Study Group. Anti-VEGF therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase 1B results. Invest Ophthalmol Vis Sci. 2002;43:E-abstract 2908.
44. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology. 2003;110:979-986.
45. Carrasquillo KG, Ricker JA, Rigas IK, et al. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic) acid microspheres. Invest Ophthalmol Vis Sci. 2003;44:290-299.
46. Honda M, Sakamoto T, Ishibashi T, et al. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther. 2000;7:978-985.
47. Mori K, Ando A, Gehlbach P, et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol. 2001;159:313-320.
48. Suzuma K, Takahara N, Suzuma I, et al. Characterization of protein kinase C β isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA. 2002;99:721-726.
49. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.
50. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98:2018-2026.
51. Seo MS, Kwak N, Ozaki H, et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol. 1999;154:1743-1753.
52. Fabbro D, Ruetz S, Bodis S, et al. PCK42- a protein kinase inhibitor with a broad therapeutic potential. Anitcancer Drug Des. 2000;15:17-28.
53. Shen WY, Yu MJT, Barry CJ, et al. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br J Ophthalmol. 1998;82:1063-1071.
54. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci. 1994;35:3178-3188.
55. Frank RN. Growth factors in age-related macular degeneration: pathogenic and therapeutic implications. Ophthalmic Res. 1997;29:341-353.
56. Soubrane G, Cohen SY, Delayre T, et al. Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig. Curr Eye Res. 1994;13:183-195.
57. Pepper MS, Ferrara N, Orci L, et al. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochim Biophys Acta. 1992;189:824-831.
58. Goto F, Goto K, Weindel K, et al. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 1993;69:508-517.
59. Renno RZ, Youssri AI, Michaud N, et al. Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2002;43:1574-1580.
60. Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived growth factor inhibits retinal and choroidal neovascularization. J Cell Physiol. 2001;188:253-263.